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Background and aim: Early detection enables the possibility for interventions to reduce 
the future burden of COPD. The Danish National Board of Health recommends that indi-
viduals .35 years with tobacco/occupational exposure, and at least 1 respiratory symptom 
should be offered a spirometry to facilitate early detection of COPD. The aim, therefore, was to 
provide evidence for the feasibility and impact of doing spirometry in this target population.
Methods: Participating general practitioners (GPs) (n = 335; 10% of the Danish GPs) recruited 
consecutively, subjects  with .35 years exposure, no previous diagnosis of obstructive lung 
disease, and at least 1 of the following symptoms: cough, dyspnea, wheezing, sputum, or recur-
rent respiratory infection. Data on age, smoking status, pack-years, body mass index (BMI), 
dyspnea score (Medical Research Council, MRC), and pre-bronchodilator spirometry (FEV1, 
FEV1% predicted, FEV1/FVC) were obtained.
Results: A total of 3.095 (51% females) subjects was included: mean age 58 years, BMI 26.3, 
and 31.5 pack-years. The majority of subjects (88%) reported MRC score 1 or 2. FEV1/FVC-
ratio # 0.7 was found in 34.8% of the subjects; the prevalence of airway obstruction increased 
with age and decreased with increasing BMI, and was higher in men and current smokers. 
According to the level of FEV1, 79% of the subjects with airway obstruction had mild to moder-
ate COPD.
Conclusions: More than one-third of the recruited subjects had airway obstruction (FEV1/ 
FVC , 0.7). Early detection of COPD appears to be feasible through offering spirometry to 
adults with tobacco/occupational exposure and at least 1 respiratory symptom.
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Introduction
COPD is a common disease, which causes substantially impaired quality of life and 
increased risk of premature death. Tobacco smoking is the most important risk factor 
for COPD in up to 90% of patients in Western societies, although environmental, 
occupational, and genetic factors also interact and play a role.1–3
In most cases COPD has its roots decades before the onset of symptoms and runs 
an insidious course over years, often with an undiagnosed initial phase.1,4,5 COPD is 
frequently diagnosed at a relatively late stage of the disease, probably because early 
symptoms of the disease are subtle and unrecognized due to individual perception 
and interpretation.5 Early symptoms of the disease may not be evident, although 
airflow obstruction is present on spirometry. Patients suffering from more severe 
COPD have substantial limitations in activities of daily living, leading to poor health-
related quality of life and disability. Early recognition of cases may therefore have International Journal of Chronic Obstructive Pulmonary Disease 2011:6 submit your manuscript | www.dovepress.com
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the potential to reduce the future burden of COPD for both 
morbidity and mortality.5
In Denmark, as in any country, general practitioners and 
family physicians (GPs) are on the frontline for prevention 
and early diagnosis of COPD. The GPs should therefore be 
encouraged to take the lead in implementing spirometry, 
as well as the recommendations of the updated treatment 
guidelines. In keeping with this, the Danish National Board 
of Health recommends that smokers/ex-smokers and indi-
viduals with relevant occupational exposure over 35 years 
with at least 1 respiratory symptom should be offered spirom-
etry to facilitate early detection of COPD.6 This approach 
was recently adopted in the COPD guidelines generated by 
the Danish Society for General Practice.7
The aim of this general practice-based study was to 
investigate the feasibility for implementing the recommenda-
tion of spirometry in the defined risk population.
Material and methods
Denmark has approximately 3600 GPs, covering a population 
of 5.4 million. We aimed on a voluntary basis to include a 
representative sample comprising at least 200 GPs from 
all over Denmark. Written information about the project, 
as well as the invitation to participate, was distributed to all 
the interested GPs by the sponsoring companies’ local rep-
resentatives. Each of the participating GPs was expected to 
screen at least 30 consecutive subjects who attended the 
practice and fulfilled the eligibility criteria.
Subjects were eligible for the study provided they fulfilled 
the following inclusion criteria: 1) age $ 35 years; 2) smoker/
ex-smoker or relevant occupational exposure; 3) $one 
respiratory symptom (dyspnea, cough, wheeze, sputum, and/
or recurrent chest infections); and not the following exclusion 
criteria: 1) unable to perform spirometry; 2) previous diag-
nosis of obstructive lung disease (asthma and/or COPD) or 
other chronic respiratory disease.
The case record form (CRF) consisted of 2 parts: 1) a ques-
tionnaire filled in by the participant for age, gender, height, 
body weight, smoking status, daily tobacco consumption, years 
of smoking, airway symptoms (cough, dyspnea, wheezing, 
sputum, and recurrent lower airway infection), and severity 
of dyspnea (graded according to Medical Research Council, 
MRC;8 2) data obtained by the GP in his/her own practice 
on spirometry (FEV1, expressed in absolute value and 
as a percentage of the predicted value, FVC, and FEV1/
FVC ratio), severity of COPD (graded according to GOLD9), 
the participants’ wishes in relation to smoking cessation 
(including need for nicotine replacement therapy or 
  prescribed medication), and the final decision whether or not 
further intervention is indicated. All data from the individual 
CRF were entered into a consolidated web-based database; 
and on registration the body mass index (BMI), FEV1/FVC 
ratio, severity of COPD (based on FEV1% predicted), and 
number of pack-years was automatically calculated. Consul-
tants from the sponsoring companies performed quality 
control of the CRFs.
Data analysis
Data from individual participant’s records were analyzed 
focusing on the defined outcome variables; only data for 
participants with complete CRFs (95.2%) were included in 
the analyses. The FEV1 was expressed as the absolute 
value and also as a percentage of the predicted value,10 and 
the FEV1/FVC ratio as the absolute value. Predictors of an 
FEV1/FVC ratio , 0.7 were identified by means of multiple 
logistic regressions with predictor variables for gender, age, 
BMI, and smoking status. Quantitative predictor variables 
were included using smoothing splines, and tested for pos-
sible nonlinearities. In all the statistical analyses a signifi-
cance level of 5% was adopted and significance of predictor 
variables was tested by means of the likelihood ratio test. 
The results were interpreted terms of odds ratios and visual-
ized using nomograms. The statistical software R11 was used 
for the statistical   analyses. The TOP project was accepted 
by the Danish   College of General Practitioners.
According to the EFPIA code,12 and the Danish Associa-
tion of the Pharmaceutical Industry (LiF),13 the present study 
was a noninterventional trial, and approval from the scientific 
ethical committee and the Danish Medicines Agency were 
not mandatory, but they were given all relevant study 
  information. The study was approved by the Danish Data 
  Protection Agency.
Results
A total of 335 GPs participated in the study, and 3095 indi-
viduals (49% males) with complete data were included in 
the analyses. A total of 65% of the study population (62% 
males and 67% females) were current smokers, and 3% were 
never smokers. Approximately 50% of the current smokers 
stated that they were not interested in quitting smoking, and 
no difference was observed between smokers with and with-
out airway obstruction. Further characteristics of the enrolled 
subjects are given in Table 1.
The most common reported respiratory symptoms were 
dyspnea (66%) and cough (63%), whereas wheeze, sputum, 
and recurrent respiratory infection were reported by 21%, 31%, International Journal of Chronic Obstructive Pulmonary Disease 2011:6 submit your manuscript | www.dovepress.com
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and 14%, respectively. The majority of subjects (88%) 
reported dyspnea score 1 and 2, whereas 12% of the enrolled 
subjects reported dyspnea of such severity (MRC 3 to 5) that 
they fulfilled the criteria for referral to a hospital-based 
rehabilitation program. Almost half of the individuals (45%) 
reported only 1 respiratory symptom, whereas 28% reported 
2 symptoms.
Airway obstruction, defined as a FEV1/FVC ratio # 0.7, 
was found in 34.8% (n = 1079) of the enrolled subjects. The 
prevalence of airway obstruction was increasing with age, 
but airway obstruction was also found in a substantial propor-
tion of the subjects in the younger age groups (Figure 1). In 
the analysis, gender, age, BMI, and smoking status were all 
found to be significant predictors of a FEV1/FVC ratio # 0.7. 
The prevalence of airway obstruction was higher for increas-
ing age and decreasing BMI. Furthermore, the prevalence 
was also higher in men than in women, and in smokers than 
in ex-smokers and never smokers. The 95% confidence 
intervals for odds ratios of these risk factors are given in 
Table 2. A nomogram for the analysis obtained by the mul-
tiple regression model is given in Figure 2. From the 
  nomogram, individual predictions can be obtained by adding 
Table 1 Characteristics of the enrolled subjects
Males 
(n = 1503)
Females 
(n = 1594)
Age (years) 58 (36–90) 57 (36–88)
BMI (kg/m2) 27 (15–49) 26 (14–55)
Pack-years (n) 38 (0.5–175) 29 (0.1–172)*
Note: *P , 0.05.
Abbreviation: BMI, body mass index.
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Figure 1 Estimated age and gender specific prevalence of FEV1/FVC ratio # 70%.
the partial effect on each risk factor and using the sum to 
calculate the risk of having a FEV1/FVC ratio , 0.7; further-
more, the relative importance of risk factors can be seen 
directly.
Further analysis of the data for the individuals with airway 
obstruction (n = 1078) showed that the level of FEV1% 
predicted in 28% and 51%, respectively, fulfilled the criteria 
for mild and moderate COPD (Figure 3).
Discussion
Denmark has approximately 3600 GPs, covering a population 
of 5.4 million, and we aimed to include, on a voluntary basis, 
at least 200 GPs in the study from all over Denmark. How-
ever, the general interest for participating in the study 
exceeded our expectations, and a total of 335 GPs (almost 
10% of the Danish GPs) agreed to participate, and included 
3095 subjects in the study. As expected, not all of the enrolled 
GPs contributed subjects to the study sample, just as some 
of the participating GPs did not manage to enrol 30 subjects, 
but eventually more than 220 GPs contributed subjects with 
complete data for the study sample.
The present study demonstrated clearly that early detec-
tion of COPD is feasible in general practice by offering 
spirometry to individuals with relevant exposure and airway 
symptoms. Furthermore, the observed prevalence of airway 
obstruction was disturbingly high, but fortunately the major-
ity of the subjects identified with airway obstruction 
appeared, as judged by the level of FEV1% predicted, to have 
mild to moderate COPD. Using this case finding approach 
may therefore provide an opportunity for early intervention 
aimed at improving prognosis.
Compared with previous reports from the Lung Health 
study14 and the study by Zielinski and Bednarek,15 the present 
study revealed a much higher prevalence of airway obstruc-
tion (.30%), although the subjects included in the present 
study did not have a higher mean cumulative life-long tobacco 
exposure. Furthermore, studies by Miravitlles et al16 and 
Hansen et al17 have likewise reported a much lower preva-
lence of COPD, 10% and 12%, respectively. These differ-
ences may be explained by differences in recruitment of 
subjects such as age, life-time tobacco exposure (pack-years), 
marketed type of cigarettes, genetics, differences in air 
  pollution and environmental exposure, and/or pattern and 
availability of health care utilization. The case-finding design 
of offering spirometry to individuals with relevant exposure 
and at least 1 respiratory symptom used in the present study 
proved to be more cost-effective in general practice compared 
with previous reports.18International Journal of Chronic Obstructive Pulmonary Disease 2011:6 submit your manuscript | www.dovepress.com
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A ratio of FEV1 to FVC of less , 0.7 when measured 
after the administration of an inhaled bronchodilator is the 
spirometric criterion to define COPD,1,9 whereas no symptoms 
are needed. In the present study only prebronchodilator 
spirometry was performed, and some, most likely only a 
minority of the individuals identified with airway obstruction 
may have a post-bronchodilator FEV1/FVC ratio within the 
reference values. However, doing post-bronchodilator spirom-
etry was beyond the scope of the present study.   Furthermore, 
the validity of the present findings for the diagnosis of COPD 
is supported by the current UK National Institute for Clinical 
Excellence19 COPD guidance in which pre-bronchodilator 
spirometry values are used to diagnose and stage COPD.19,20
Previous studies suggest that using a fixed ratio for FEV1/
FVC as the diagnostic criterion may overestimate the 
  prevalence of COPD in the elderly and underestimate the 
prevalence in younger subjects.5,16 It has, therefore, in 
the Spanish/Latin America guidelines20 been suggested to 
use the lower limit of normal, ie, the bottom 5% of the normal 
distribution of FEV1/FVC in a healthy reference population, 
for the diagnosis of COPD. In keeping with most published 
COPD guidelines, we decided to use the fixed FEV1/FVC 
ratio, not least because this appears to be easier to handle as 
the diagnostic criterion in general practice.
In conclusion, the present study showed that early detection 
of COPD in general practice by offering spirometry to indi-
viduals with relevant exposure and airway symptoms is not 
only feasible, but identified a high proportion of individuals 
with airway obstruction. Furthermore, the majority of subjects  Points
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Figure  2  nomogram  used  for  predicting  the  probability  of  FeV1/FVC  #  70%. 
The model reported in Table 2 has been used in constructing the nomogram.
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Figure 3 Distribution of enrolled subjects with airway obstruction (FeV1/FVC # 70%) 
(n = 1078) according to severity of COPD (based on FeV1% predicted).
Table 2 Distribution of FeV1/FVC , 70 stratified on gender, smoking status, age, and BMI
Risk factor FEV1/FVC , 70 
N (%)
FEV1/FVC $ 70 
N (%)
95% CI for OR P-value
gender
  Female 527 (33.1) 1063 (66.9)
  Male 551 (36.6) 954 (63.4) [1.01–1.38] 0.039
smoking  1290 (64.5)
  smoker 713 (35.5)
  ex-smoker 343 (34.6) 647 (65.4) [0.64–0.91] 0.002
  never smoker 22 (21.5) 80 (78.5) [0.27–0.74] 0.001
Age (years)
  36–48 144 (17.9) 657 (82.1)
  49–58 262 (31.6) 566 (68.4)
  59–66 312 (41.7) 436 (58.3)
  67–90 360 (50.0) 358 (50.0) [2.20–2.84] ,0.001
BMI (kg/m2)
  14.4–23.1 327 (42.2) 447 (57.8)
  23.2–25.6 301 (39.3) 464 (60.7)
  25.7–28.7 231 (30.1) 536 (69.9)
  28.8–55.0 219 (27.7) 570 (72.3) [0.64–0.78] ,0.001
Notes: The grouping of age and body mass index (BMI) is based on quartiles. The 95% confidence intervals (CI) and P-values for odds ratios (Or) were obtained from 
multivariate logistic regression. Female smokers were set as reference levels for the Or. The Or for age and BMI correspond to an increase in interquartile range.International Journal of COPD
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with signs of COPD appeared to have mild to moderate disease, 
and secondary preventive measures may reduce the future 
burden of COPD, for both morbidity and mortality.
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